Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCLETIS-B

13.770
+1.87015.71%
Volume:15.55M
Turnover:206.93M
Market Cap:13.66B
PE:-41.86
High:13.950
Open:11.920
Low:11.890
Close:11.900
52wk High:18.750
52wk Low:1.480
Shares:992.00M
HK Float Shares:992.00M
Volume Ratio:2.94
T/O Rate:1.57%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.329
ROE:-12.77%
ROA:-12.32%
PB:6.68
PE(LYR):-41.86
PS:5277.39

Loading ...

Ascletis Reports ASC47 Combo Shows 56% Greater Weight Loss Than Semaglutide Alone

MT Newswires Live
·
Sep 22

ASCLETIS-B (01672): ASC47 Combined with Semaglutide Demonstrates Up to 56.2% Relative Improvement in Weight Loss Efficacy Compared to Semaglutide Monotherapy in Obese Subjects

Stock News
·
Sep 22

ASCLETIS-B (01672) Issues 295,600 Shares Following Stock Option Exercises

Stock News
·
Sep 18

ASCLETIS-B (01672) Reports Breakthrough Phase III Results for First-in-Class FASN Inhibitor Denifanstat (ASC40) in Acne Treatment at 2025 EADV Annual Meeting

Stock News
·
Sep 18

Ascletis Presented Phase Iii Study Results of First-in-Class Fasn Inhibitor Denifanstat (Asc40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (Eadv) Congress 2025

THOMSON REUTERS
·
Sep 18

Hong Kong Stocks Movement | ASCLETIS-B (01672) Surges Over 5% as ASC30 Demonstrates Superior Efficacy and Safety Profile with Multiple Catalysts Expected in Second Half

Stock News
·
Sep 17

Ascletis Presented Results From Cohorts 1 and 2 of 28-Day Multiple Ascending Dose Study of Its Oral Small Molecule Glp-1R Agonist Asc30 at the 61St European Association for the Study of Diabetes (Easd) Annual Meeting

THOMSON REUTERS
·
Sep 17

ASCLETIS-B (01672) Reports Results from Cohorts 1 and 2 of 28-Day Multiple Ascending Dose Study of ASC30 Oral Small Molecule GLP-1R Agonist at 61st European Association for the Study of Diabetes Annual Meeting

Stock News
·
Sep 17

Hong Kong Stock Alert | ASCLETIS-B (01672) Surges Over 4% in Afternoon Trading as Clinical Data Shows Ultra-Long Half-Life, ASC30 Poised for Quarterly Formulation

Stock News
·
Sep 15

Hong Kong Stocks Return to Winning Form as Stocks End in Green Friday; Hesai Group Prices Hong Kong IPO

MT Newswires Live
·
Sep 12

Ascletis Controlling Shareholders Lock-up Shares Ahead of Clinical Data Readout; Shares Up 5%

MT Newswires Live
·
Sep 12

ASCLETIS-B (01672) Receives Voluntary Share Lock-up Commitment from Controlling Shareholders

Stock News
·
Sep 12

HK Movers | Biotech Stocks Plunge. Ascletis Pharma down 14%; Clover Bio, Transcenta down over 10%; Beigene, HBM Holdings down over 8%; Jacobio down over 7%

Tiger Newspress
·
Sep 11

Ascletis Pharma (SEHK:1672) Reports Promising Data For ASC30 Obesity Treatment In U.S. Trials

Simply Wall St.
·
Sep 11

ASCLETIS-B (01672) Issues 98,000 Shares Following Stock Option Exercise

Stock News
·
Sep 10

Soochow Securities Maintains "Buy" Rating on ASCLETIS-B (01672): ASC30 Expected to Launch Quarterly Formulation

Stock News
·
Sep 10

Hong Kong Stock Alert | ASCLETIS-B (01672) Surges Over 5% in Early Trading as ASC30 Injectable Shows 75-Day Half-Life, Enabling Potential Quarterly Dosing

Stock News
·
Sep 10

BRIEF-Ascletis Announces Results Of Subcutaneous Depot Maintenance Formulation Of Small Molecule GLP-1R Agonist ASC30 Testing

Reuters
·
Sep 09

Ascletis Pharma Says Asc30 Shows 75-Day Half-Life In U.S. Phase Ib Study

Reuters
·
Sep 09

Ascletis Announces Ultra-Long-Acting Subcutaneous Depot Maintenance Formulation of Small Molecule Glp-1R Agonist Asc30 Demonstrated an Observed Half-Life of 75 Days in Participants With Obesity

THOMSON REUTERS
·
Sep 09